Alpha Cognition Retained Earnings (Accumulated Deficit) 2020-2024 | ACOG
Alpha Cognition retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Alpha Cognition Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-63 |
| 2022 |
$-50 |
| 2021 |
$-38 |
| 2020 |
$-18 |
| 2019 |
$-13 |
Alpha Cognition Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-69 |
| 2024-03-31 |
$-68 |
| 2023-12-31 |
$-62 |
| 2023-09-30 |
$-58 |
| 2023-06-30 |
$-54 |
| 2023-03-31 |
$-52 |
| 2022-12-31 |
$-50 |
| 2022-09-30 |
$-46 |
| 2022-06-30 |
$-44 |
| 2022-03-31 |
$-41 |
| 2021-12-31 |
$-38 |
| 2021-09-30 |
$-35 |
| 2021-06-30 |
$-31 |
| 2021-03-31 |
$-31 |
| 2020-12-31 |
$-18 |
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$-13 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
|
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|
